Who are Regeneron Pharmaceuticals's decision-makers?
Regeneron Pharmaceuticals is led by Leonard S. Schleifer. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Leonard S. Schleifer
- CFO/key exec
- Christopher Fenimore
- Founded
- 1988
- Employees
- 14,000+
- HQ
- Tarrytown, NY
- Status
- Nasdaq: REGN
- Leonard S. SchleiferCo-Founder, President and Chief Executive OfficerCEO since foundingBuilt Regeneron into a science-led commercial biotechnology company.
- George D. YancopoulosCo-Founder, President and Chief Scientific OfficerCSO since founding eraLeads discovery, VelociSuite technology, and R&D culture.
- Christopher FenimoreChief Financial OfficerCFO since 2021Oversees finance and investor operations.
- Marion McCourtExecutive Vice President and Head of CommercialCommercial leaderLeads commercialization across ophthalmology, immunology, oncology, and rare disease.
Who leads Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Regeneron Pharmaceuticals?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Regeneron Pharmaceuticals organized as it scales?
Regeneron Pharmaceuticals operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Regeneron Pharmaceuticals leadershipRegeneron Pharmaceuticals annual reports
Regeneron Pharmaceuticals — frequently asked questions
